Search Within

Prasad S Adusumilli

  1. "Hematologic Malignancies Research"
Formats
  1. Meeting Abstract (22)
  2. Journal Article (16)
Groups
  1. Center for Hematologic Malignancies (38)
  2. Department of Medicine (38)
  3. GSK Faculty (38)
  4. Hematologic Malignancies Research (38)
  5. Hematologic Malignancies, Division of (38)
  6. Surgery (38)

More Groups

People
  1. Michel Sadelain (33)
  2. Valerie Rusch (21)
  3. David Jones (11)
  4. William Travis (11)
  5. Jonathan Villena-Vargas (10)
  6. Aurore Morello (9)

More People

Years
  1. 2021 (3)
  2. 2020 (1)
  3. 2019 (2)
  4. 2018 (1)
  5. 2017 (3)
  6. 2016 (4)

More Years

Publications
  1. Journal of Thoracic Oncology (12)
  2. Cancer Research (3)
  3. Clinical Cancer Research (3)
  4. Journal of Clinical Oncology (3)
  5. Cancer Discovery (2)
  6. Cancer Immunology, Immunotherapy (2)

More Publications

Publishers
  1. Elsevier Inc. (12)
  2. American Association for Cancer Research (8)
  3. Nature Publishing Group (4)
  4. Springer (4)
  5. American Society of Clinical Oncology (3)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (38)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Promoting functional persistence in solid tumor CAR T-cell therapy: Mesothelin-targeted CAR (M28z1XXPD1DNR) with T-cell intrinsic PD1 dominant negative receptor
    Meeting Abstract

    Adusumilli, P. S.; Amador, A. M.; Chintala, N.; Hou, Z.; Offin, M.; Pineda, J.; Senechal, B.; Quach, H. T.; Bellis, R.; Banerjee, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab
    Journal Article

    Adusumilli, P. S.; Zauderer, M. G.; RivieĢ€re, I.; Solomon, S. B.; Rusch, V. W.; O'Cearbhaill, R. E.; Zhu, A.; Cheema, W.; Chintala, N. K.; Halton, E.; more...
    Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing
    Journal Article

    Wang, X.; Borquez-Ojeda, O.; Stefanski, J.; Du, F.; Qu, J.; Chaudhari, J.; Thummar, K.; Zhu, M.; Shen, L. B.; Hall, M.; more...
    Molecular Therapy - Methods & Clinical Development (2021)

    Fulltext@MSK | Save
  • Regional delivery of clinical-grade mesothelin-targeted CAR T cells with cell-intrinsic PD-1 checkpoint blockade: Translation to a phase I trial
    Meeting Abstract

    Kiesgen, S.; Linot, C.; Quach, H. T.; Saini, J.; Bellis, R.; Banerjee, S.; Hou, Z.; Chintala, N. K.; Sadelain, M.; Adusumilli, P. S.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R.; Zhu, A.; Ngai, D.; McGee, E.; Chintala, N.; Messinger, J.; Cheema, W.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R. E.; Zhu, A.; Ngai, D. A.; McGee, E.; Chintala, N. K.; Messinger, J. C.; Vincent, A.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy - A preliminary report
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M.; Rusch, V.; O'Cearbhaill, R.; Ngai, D.; Chintala, N.; Halton, E.; Diamonte, C.; Modi, S.; Solomon, S.; more...
    Molecular Therapy (2018)

    Fulltext@MSK | Save
  • Converting tumor-mediated PD-L1 inhibition into CAR T-cell costimulation to potentiate thoracic cancers immunotherapy
    Meeting Abstract

    Morello, A.; Chen, N.; Cherkassky, L.; Sadelain, M.; Jones, D.; Adusumilli, P.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma
    Journal Article

    Zauderer, M. G.; Tsao, A. S.; Dao, T.; Panageas, K.; Lai, W. V.; Rimner, A.; Rusch, V. W.; Adusumilli, P. S.; Ginsberg, M. S.; Gomez, D.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: Expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
    Journal Article

    Eguchi, T.; Kadota, K.; Mayor, M.; Zauderer, M. G.; Rimner, A.; Rusch, V. W.; Travis, W. D.; Sadelain, M.; Adusumilli, P. S.
    Oncotarget (2017)

    Fulltext@MSK | Save